In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more. Read the full coverage here: Surgery confers higher 5-year survival rates than radiotherapy in early-stage lung cancer First-line combination extends PFS in lung cancer subgroup Pembrolizumab improves outcomes in early-stage resectable lung cancer Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC Severe myelosuppression common after chemotherapy for small cell lung cancer References: Hart L, et al. Cancer Med. 2023;doi:10.1002/cam4.5738. Kanda S, et al. Abstract LBA9009. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Press Release Udelsman B, et al. Abstract 275. Presented at: American Association for Thoracic Surgery Annual Meeting; May 6-9, 2023; Los Angeles. Wakelee H, et al. Abstract LBA100. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Ver todos los episodios